[{"pageContent":"Pharmaceutical and Biotech Policy \nIssues\nPUBPOL 2350\nOctober 31, 2023","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":1,"lines":{"from":1,"to":4}}}},{"pageContent":"2","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":2,"lines":{"from":1,"to":1}}}},{"pageContent":"3","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":3,"lines":{"from":1,"to":1}}}},{"pageContent":"4","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":4,"lines":{"from":1,"to":1}}}},{"pageContent":"5","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":5,"lines":{"from":1,"to":1}}}},{"pageContent":"6","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":6,"lines":{"from":1,"to":1}}}},{"pageContent":"7","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":7,"lines":{"from":1,"to":1}}}},{"pageContent":"Are you enjoying this course? \nThe Brooks School may be right for you! \nMajor in Health Care P\no\nlicy or Public Policy \nInternal Transfer Information Session \nWednesday, November 1, 2023 \n4:30PM \n–\n5:30PM in MVR 2250 \nQuestions?   \nBrooks_admissions@cornell.edu","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":8,"lines":{"from":1,"to":12}}}},{"pageContent":"Today’s Topics\n1.\nDevelopment and Approval: \nDiscuss how new drugs are developed. \nHow long does it take and how much money is required, on \naverage?\n2.\nWhat happens when a drug patent \nexpires\n \nand generic firms enter?\n3.\nMarketing: \nWhy do biotech and pharmaceutical firms spend so \nmuch money marketing drugs?\n4.\nDrug Prices\n: Why are prescription drug prices so much lower in \nother high\n-\nincome countries than in the U.S.?\n5.\nPolicies to Reduce U.S. Drug Prices\n: discuss the impact of allowing \nthe U.S. government \n(\nMedicare\n) negotiate\n \ndrug prices with \nbiopharmaceutical \nfirms\n, \nbeginning \nin \n2026.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":9,"lines":{"from":1,"to":36}}}},{"pageContent":"Developing a New Drug is a Long, Uncertain, and Expensive\nProposition: Typical Timeline\nYears\nDrug Development Timeline\nFood and Drug \nAdmin. (FDA) Review\nPhase 2\n100\n–\n300 Patient Volunteers Used to \nLook for Efficacy \n–\n \nDoes the Drug \nWork?\nPreclinical Testing\nLaboratory and Animal Testing\n16\n14\n12\n10\n8\n6\n4\n2\n0\nDiscovery\n(2\n–\n10 Years)\nPhase 1 \n20\n–\n80 Healthy Volunteers Used to \nDetermine Safety and Dosage\nPhase 3\n1,000\n–\n5,000 Patient Volunteers\nEffective in large sample?\nSide effects with long\n-\nterm use?\nAdditional Post\n-\nMarketing \nTesting\nSource: PhRMA Pharmaceutical Industry Profile 2003, Chapter 1: Increased Length and Complexity of the \nResearch and Development Process. DiMasi, JA, Hansen, RW, Grabowski, HG. “The Price of Innovation: new \nestimates of drug development costs.” \nJournal of Health Economics\n. 2016.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":10,"lines":{"from":1,"to":52}}}},{"pageContent":"Developing a New Drug is a Long, Uncertain, and Expensive\nProposition: Success by Stage\n5,000\n–\n10,000 \nScreened in \nDiscovery\n250\nEnter Preclinical \nTesting\n8\nEnter \nClinical \nTesting\nNew Drug Success \nRates by Stage\n1\nApproved \nby the FDA\nSource: PhRMA Pharmaceutical Industry Profile 2003, Chapter 1: Increased Length and Complexity of the \nResearch and Development Process. DiMasi, JA, Hansen, RW, Grabowski, HG. “The Price of Innovation: new \nestimates of drug development costs.” \nJournal of Health Economics\n. 2016.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":11,"lines":{"from":1,"to":24}}}},{"pageContent":"12% of Drugs That Start Phase 1 are Approved, and it Takes\nan Average of 8 Years (same % with more recent data) \nNote: Mean time between phases is reported\ni\nn \n(parentheses)\n60%\n36%\n62%\n90%\n12%\n0%\n10%\n20%\n30%\n40%\n50%\n60%\n70%\n80%\n90%\n100%\nPhase 1\n-\n2\n(1.7 years)\nPhase 2\n-\n3\n(2.5 years)\nPhase 3\n-\nNDA/BLA\nSub\n(2.6 years)\nNDA/BLA Sub\nNDA/BLA App\n(1.3 years)\nPhase 1\n-\nNDA/BLA\nApp\n(8.1 years)\nTransition Probability (%)\nPhase Transition Probabilities and Overall Clinical Approval \nSuccess Rates\nSource:  DiMasi  et al. 2016.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":12,"lines":{"from":1,"to":47}}}},{"pageContent":"Drug Development Case Study: Eli Lilly Was Ready to Test \nMounjaro\n \nin a Phase 3 Type\n-\n2 Diabetes Trial in \n2019\n▪\nMost Type\n-\n2 diabetes patients take a generic drug, metformin, by \nitself or in combination with another drug from a different class \nwith a different mechanism of action (+ exercise and healthy diet).\n▪\nHowever, many patients still do not meet the recommended \nblood sugar level (i.e., an HbA1c \nlab\n \ntest\n \nleve\nl\n \nof less than 7.0).\n▪\nMounjaro\n \n(brand name) is a GLP\n-\n1 receptor \nagonist\n \nthat helps \nrevive insulin secretion.\n▪\n“\nTirzepatide\n \n(scientific/generic name) lowers fasting and \npostprandial glucose concentration, decreases food intake, and \nreduces body weight in patients with type\n2 diabetes” (from \nMounjaro’s\n \nFDA\n-\napproved \nlabel)\n.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":13,"lines":{"from":1,"to":49}}}},{"pageContent":"Mounjaro’s\n \nPhase 3 Randomized Controlled Trial (RCT)\nIn 4 \nseparate trials\n, \nMonjaro\n \nwas compared w/o metformin vs. a \nplacebo; and separately versus 3 insulin drugs.\nPatients with \n(uncontrolled) \nType\n-\n2\nDiabetes\nN = 469\nN = 468\nMounjaro\n \n+ metformin\nOzempic + metformin\nEfficacy:\n   \n-\n \nReduction in HbA1c\n \n2.3\n \n \n \n1.8\n   \n-\n \n% patients hitting 7.0\n \n86% \n                            \n79%\n   \n-\n \nPounds lost\n \n \n28\n \n \n  \n13\n% of patients with: \n   \n-\n \nAbdominal pain\n \n5%\n \n \n  \n4%\n   \n-\n \nDiarrhea\n \n \n18%\n \n \n  \n9%\n   \n-\n \nNausea\n \n \n17%\n \n \n  \n4%\n   \n-\n \nVomiting\n \n \n9%\n \n \n  \n2%\nControl\nGroup\nTreatment\nGroup\nPrimary\nEndpoint\nSecondary\nendpoint","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":14,"lines":{"from":1,"to":104}}}},{"pageContent":"1)\nShould the Food and Drug \n      \nAdministration (FDA) approve \n           \nMounjaro\n?\n    \n2)  What decision rule does the FDA use?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":15,"lines":{"from":1,"to":9}}}},{"pageContent":"How the FDA Makes Approval Decisions\nFDA’s decision rule: \nAre the \nhealth \nbenefits\n \n(actual or \nexpected) better than \nor same as the \ncontrol group?  \nIf so, do the health \nbenefits \noutweigh the \npossible side effects\n \nor safety issues? \nPhase 4 Studies\nThe FDA often mandates \nPhase 4 (post\n-\napproval) \nstudies as a condition for \napproval, to explore \nwhether safety issues in \na RCT persist in a \nbroader patient \npopulation.\nNOT Prices \nThe FDA \ndoes not\n \nconsider the drug’s \nprice.  Ditto with\nEuropean regulatory\nbodies.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":16,"lines":{"from":1,"to":35}}}},{"pageContent":"Mounjaro’s\n \nApproved Label\nPhysicians can use a drug “off\n-\nlabel” once it is approved. \n•\nMounjaro\n \nfor Type\n-\n1 diabetes, for example\n•\nMounjaro\n \nfor weight loss for non\n-\nType\n-\n2 diabetes \npatients, for example\nBut pharmaceutical firms \ncannot market off\n-\nlabel\n, and \nhealth insurers are more likely to refuse to pay when a \ndrug is used off\n-\nlabel \n(\no\nr\n \nrequire prior \nauthorization\n \nbefore agreeing to pay\n).\nFDA Approves a Drug \nfor an Indication\n, Not a Drug","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":17,"lines":{"from":1,"to":42}}}},{"pageContent":"About 20% of Prescriptions Are for Off\n-\nLabel Uses, and a \nMajority for Some Drugs\nPhysician Determination of \nOn\n-\n \nvs Off\n-\nLabel \nIn a separate survey of 1,200 \nphysicians, only \n55% could \ncorrectly determine \nwhether or \nnot\n \na particular \nuse of a drug was \non\n-\nlabel (supported by RCT \nevidence) or off\n-\nlabel.\nOff\n-\nLabel Prescription Efficacy \nOnly 30% of off\n-\nlabel \nprescriptions were \nsupported by \nevidence of clinical efficacy \n(e.g., \nresults from a published study \nafter\n \nthe drug was approved).\nSource: Pan, \nClinical Pharmacology & Therapeutics\n, May 2012.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":18,"lines":{"from":1,"to":43}}}},{"pageContent":"Why Are Biotech and Pharmaceutical Firms Willing \nto Spend So Much to Develop a New Drug?\n179\n413\n1044\n2558\n1970s\n1980s\n1990 - early\n2000s\n2013\nSource: \nDiMasi\n \net al., 2016,  \nJournal of Health Economics\n.\nTotal Cost:\nRepresents the \ntotal amount \nneeded to spend \non a drug \nportfolio to be \n“assured” \nstatistically that \none will be \napproved\nDrug Development Cost\n($ Millions, in real terms)","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":19,"lines":{"from":1,"to":29}}}},{"pageContent":"20\nPatents\n \nAllow a Firm to Recover R&D Costs; \nExpiration Triggers Fierce Competition\nGeneric Protection\nPatents\n \nprevent other \nfirms from producing a \ngeneric\n, or bioequivalent, \ncopy of a drug for the 20\n-\nyear life of a patent.\nBioequivalent Competitors\nWithout patent protection, any firm \ncould take a drug the day it is approved \nby the FDA and \n“reverse\n-\nengineer\n” \nit. \nThey could sell a bioequivalent version \nof the drug \nwithout having invested \nmillions of dollars developing it. \nCompetitive Pricing \nMultiple firms in \ncompetition would \nlead to \ndrug prices close to \nproduction cost\n, meaning \nresearch and development \n(R&D) costs couldn’t be \nrecouped.\nPatent Pricing\nPatents allow a firm to \ncharge a price above the \ncost of producing\n \nthe \ndrug to make a profit and \nrecoup R&D costs.\nhttps://\nwww.iconfinder.com\n/\nmrpixel\nhttps://\nwww.iconfinder.com\n/\niconsets\n/security\n-\ndouble\n-\ncolour\n-\nblue\n-\nblack\n-\nvol\n-\n3\nhttps://\nwww.iconfinder.com\n/\nlaurareen","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":20,"lines":{"from":1,"to":71}}}},{"pageContent":"21\nProduct Life Cycle: Revenue Grows Steadily \nOver an Extended Time, Then Falls Precipitously\nSource: DiMasi and Grabowski, 2012.\n-100\n-50\n0\n50\n100\n150\n200\nMillions of 2000 Dollars\nYear\nDrug\nLaunch\nPatents \nallow a firm \nto set a price \nabove \nproduction \ncosts\nRed line = profit of the drug\nLosses when\ndeveloping drug\nE\nntry\n \nof\ng\neneric drugs\n \ndecreases \nprofits\nonce\npatents\nexpire","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":21,"lines":{"from":1,"to":36}}}},{"pageContent":"22\nSource: \nDusetzina\n \net al., 2023\nLoss \nDrivers\n \nfor\nBranded Dru\ng\n•\nAutomatic \nsubstitution at \npharmacy \n•\nHealth \ninsurers set \nlower co\n-\npays \nfor generic \nversus \nbranded drugs\nOnce Patents Expire Generic Versions Enter and 97% of Patients \nEventually Shift From the Branded to a Generic Product","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":22,"lines":{"from":1,"to":26}}}},{"pageContent":"Generics Cut the Price Substantially Once They Enter","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":23,"lines":{"from":1,"to":1}}}},{"pageContent":"Generic Drugs Now Account for 91% of Prescriptions Filled\n(but a Much Smaller % of Pharma Spending)\nGeneric Share of Total Prescriptions, 1984\n-\n2022\n18.6\n32.0\n36.0\n49.7\n56.4\n74.5\n80.0\n86.0\n88.0\n88.7\n89.5\n90.0\n90.0\n90.0\n90.0\n91.0\n1984\n1989\n1994\n1999\n2004\n2009\n2011\n2013\n2014\n2015\n2016\n2017\n2018\n2019\n2020\n2022\nYears\nSources: For\n1984\n-\n2004, IMS Health\nNational Prescription Audit archives; for 2005\n-\n2009, IMS Health \nNational Sales Perspectives; 2010\n-\n2012, IMS; GPHA, 2015; for 2018, IQVIA Medicine Use and Spending in \nthe U.S., May 2019.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":24,"lines":{"from":1,"to":49}}}},{"pageContent":"Patents Do Not Provide “Perfect” Monopolies\nPatents provide a (temporary) monopoly on a \ncompound\n, not a monopoly \non treating a \nhealth condition\nAlternative \nTreatment Choices\nSome people with a \nhealth condition \nmay decide not to \nbe treated, or to be \ntreated without \npharmaceuticals\nSame\n-\nDisease Competition\nA company with a patent usually competes \nagainst \nother molecules\n \nthat treat the same \ndisease:\n▪\nOther patent\n-\nprotected molecules\n▪\nSome molecules that are now generic\nInternational \nEnforcement\nU.S. patents are \nnot always \nenforced abroad","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":25,"lines":{"from":1,"to":34}}}},{"pageContent":"Marketing Spending Has Declined in Past Decade But Is \nStill Focused on \nPhysicians\n, Not Patients\n11.4\n29.9\n32.3\n29.3\n29.9\n1996\n2005\n2008\n2010\n2016\nIndustry Spending, $ Billions\n \n \n  \n$ Billions\nDetailing\n$5.6\nSamples\n$13.5\nMD Meetings\n$1.0\nDirect\n-\nto\n-\nconsumer\nadvertising\n$9.6\nOther\n$0.2\nTotal\n$29.9\nSource: SK&A, \n2012 U.S. Pharmaceutical Promotion Spending; Schwartz and Woloshin, JAMA, 2019\n.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":26,"lines":{"from":1,"to":39}}}},{"pageContent":"What is Detailing?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":27,"lines":{"from":1,"to":1}}}},{"pageContent":"John Oliver’s Take","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":28,"lines":{"from":1,"to":1}}}},{"pageContent":"Why Do Pharmaceutical\n \nFirms Spend\n$30 Billion Per Year on\n \nMarketing/Advertising?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":29,"lines":{"from":1,"to":6}}}},{"pageContent":"Product Life Cycle: Revenue Grows Steadily \nOver an Extended Time, Then Falls Precipitously\nSource: DiMasi and Grabowski, 2012.\n-100\n-50\n0\n50\n100\n150\n200\nMillions of 2000 Dollars\nYear\nDrug\nLaunch\nIt often takes \n10 years for \ndrug sales to \npeak as MDs \nand patients \nlearn\n \nabout \nthe new drug\nRed line: profit of the drug\nLosses when\ndeveloping drug","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":30,"lines":{"from":1,"to":26}}}},{"pageContent":"The Slow Uptake\nSource: Berndt, \nHealth Affairs\n, 2001.\nExperience Goods: \nPharmaceutical drugs are \nexperience goods\n; \nphysicians and patients need to \ntry\n \nthe product \nin order to\n \ndetermine \nwhether it’s valuable to them.\nCompanies that make experience goods tend to market \nheavily \nin order to\n \nprovide \ninformation\n \nabout the value of \ntheir product. (But does marketing also \npersuade\n \npeople?)\nExperience Goods \nMakers \nHeavy Marketing\nPotential Value of \nProduct\nImage Source: https://\nwww.iconfinder.com\n/\nrasulh","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":31,"lines":{"from":1,"to":37}}}},{"pageContent":"Conclusions, Part 1 of Pharma\n▪\n \nDeveloping a drug takes a long time, is expensive, and \n   \nis not guaranteed to work.\n▪\n \nPatents allow pharmaceutical firms that successfully launch \n   \na new drug to make $ on it, thus providing incentives for\n   \nthem to incur the uncertainty and large expenditures involved.\n▪\n \nGeneric drugs, which have relatively low prices, now account\n   \nfor 91% of all prescriptions.\n▪\n \nFirms market to physicians and patients to convey information\n   \nabout the drugs, so they will try them (experience goods).\n▪\n \nMarketing is especially important because once the patent \n   \nexpires, generic companies will take over the market.\n▪\n \nThe government closely regulates the drug development, \n   \nmanufacturing, and marketing processes.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":32,"lines":{"from":1,"to":33}}}},{"pageContent":"Percentage of Personal Health Care Spending by Type of Service\n39%\n44%\n47%\n41%\n37%\n37%\n22%\n22%\n22%\n26%\n25%\n24%\n4%\n7%\n10%\n11%\n11%\n9%\n11%\n9%\n6%\n7%\n11%\n11%\n23%\n18%\n16%\n15%\n16%\n19%\n1960\n1970\n1980\n1990\n2000\n2021\nOther\nRx Drugs\nPhysician \nServices\nHospitals\nHome care/\nnursing home\nSource: CMS and Hartman et al., 2023.\nPharmaceutical Expenditure Share Has Almost Doubled\nOver the Past 40 Years","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":33,"lines":{"from":1,"to":47}}}},{"pageContent":"Protease Inhibitor Cocktails Reduced HIV Mortality Sharply\nSome of the Increased Use of Prescription \nDrugs Has Clearly Improved Health\nCovid vaccines are another good example","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":34,"lines":{"from":1,"to":4}}}},{"pageContent":"Other High\n-\nIncome Countries Spend Much Less Than the \nU.S. on Prescription Drugs, Largely Due to Lower \nPrices\nPer Capita Prescription Drug Spending, 2022\n$402\n$517\n$595\n$748\n$681\n$766\n$1,043\n$914\n$836\n$1,432\nDenmark\nUK\nSpain\nItaly\nAustralia\nFrance\nGermany\nCanada\nJapan\nUSA\nSource: Organization for Economic Cooperation and Development, OECD, 2023.","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":35,"lines":{"from":1,"to":27}}}},{"pageContent":"Drug prices in the U.S. are much higher than in peer countries, 2018.\nSource: Mulcahy et al., 2021.\nU.S. Pays Much Higher Prices for Drugs Than Other Countries","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":36,"lines":{"from":1,"to":3}}}},{"pageContent":"Why are drug prices so much lower in \nEurope, Japan, and Canada than the \nUnited States?\nWhat would happen if the U.S. \ngovernment regulated prices like \nEurope and Japan do, or if we had a \nsingle payer system?","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":37,"lines":{"from":1,"to":7}}}},{"pageContent":"Higher U.S. Drug Spending Driven by Higher \nPrices\n \nand \nGreater Use of \nNew\n/Expensive Drugs but Not a Greater \nQuantity\n \nof Prescriptions\nPrices Set in Market \nU.S. drug prices are set in the \nmarket\n \nby pharmaceutical \nfirms, who negotiate with \nhundreds\n \nof private health \ninsurers (but not the U.S. government, by law, until 2026).\nInternationally, Firms Negotiate with One Entity\nA major reason prescription drug prices are about 60% lower \nin other developed countries is that pharma firms negotiate \nwith \none entity\n \n(the government), which gives the \ngovernment negotiating power via a take\n-\nit\n-\nor\n-\nleave\n-\nit threat. \nJapan and EU Policies \nEU and Japan also have policies that favor the \nuse of older less expensive drugs, which creates\nadditional negotiating power for a single entity.\nImage Source: https://\nwww.iconfinder.com\n/\nMakoto_msk","metadata":{"source":"docs/PUBPOL_2350/Pharma and Biotech_Policy_2023.pdf","pdf":{"version":"1.10.100","info":{"PDFFormatVersion":"1.7","IsAcroFormPresent":false,"IsXFAPresent":false,"Title":"Creative Presentations","Author":"Rocketo Graphics","Creator":"Microsoft® PowerPoint® for Microsoft 365","Producer":"Microsoft® PowerPoint® for Microsoft 365","CreationDate":"D:20231031093143-04'00'","ModDate":"D:20231031093143-04'00'"},"metadata":{"_metadata":{"pdf:producer":"Microsoft® PowerPoint® for Microsoft 365","dc:title":"Creative Presentations","dc:creator":"Rocketo Graphics","xmp:creatortool":"Microsoft® PowerPoint® for Microsoft 365","xmp:createdate":"2023-10-31T09:31:43-04:00","xmp:modifydate":"2023-10-31T09:31:43-04:00","xmpmm:documentid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB","xmpmm:instanceid":"uuid:F3927A32-C2D8-4F74-A40A-9949A114E2CB"}},"totalPages":38},"loc":{"pageNumber":38,"lines":{"from":1,"to":44}}}}]